Exenatide: What It Is and How the First GLP-1 Agonist Works

At a glance

What is exenatide?

Exenatide is a GLP-1 receptor agonist, a peptide that mimics the natural gut hormone GLP-1. It is a synthetic copy of exendin-4, a molecule first found in the venom of the Gila monster, a large venomous lizard native to the southwestern United States. It was developed by Amylin Pharmaceuticals and Eli Lilly, later marketed by AstraZeneca, and sold as Byetta (a twice-daily injection) and Bydureon BCise (a once-weekly injection).

The history of exenatide

Exenatide began with a lizard. In the early 1990s, the endocrinologist John Eng studied the venom of the Gila monster and identified a hormone-like peptide, exendin-4, that closely resembled human GLP-1 but lasted far longer in the body. Human GLP-1 breaks down within minutes, but the lizard version persisted for hours, which made it a practical drug candidate. That discovery became exenatide, and in 2005, Byetta became the first GLP-1 drug approved by the FDA, launching the entire class that now includes liraglutide, semaglutide, and tirzepatide. A once-weekly version, Bydureon, followed in 2012. In 2024, AstraZeneca discontinued both Byetta and Bydureon BCise in the U.S. for business reasons. A generic version of Byetta launched in May 2025, so twice-daily exenatide is still available.

How does it work?

Exenatide lowers blood sugar by activating the GLP-1 receptor, mimicking a gut hormone the body releases after meals. Through that receptor it triggers glucose-dependent insulin release, which keeps the risk of hypoglycemia low on its own, while lowering glucagon, slowing the rate at which the stomach empties, and reducing appetite. Because it is based on the lizard peptide exendin-4 rather than human GLP-1, it resists the enzyme that rapidly breaks down natural GLP-1, so it lasts long enough to be dosed twice daily. The extended-release Bydureon formulation encases the peptide in tiny microspheres that release it slowly, allowing once-weekly dosing. In its trials it produced moderate reductions in A1c along with some weight loss.

Is it FDA-approved?

Yes. Byetta was approved in 2005 as the first GLP-1 drug, and the once-weekly Bydureon followed in 2012. AstraZeneca discontinued both in the U.S. market in 2024 for commercial reasons, not because of a safety problem. A generic version of twice-daily exenatide is now sold.

What is exenatide prescribed for?

Exenatide is prescribed to improve blood sugar control in adults with type 2 diabetes, alongside diet and exercise. It is not a treatment for type 1 diabetes. For the long-acting Bydureon form, it should not be used by people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.

What are the side effects?

The most common side effects are gastrointestinal, with nausea especially common:

• Nausea
• Vomiting
• Diarrhea
• Feeling jittery
• Dizziness
• Headache
• Decreased appetite Less common but more serious risks include:
• Pancreatitis, or inflammation of the pancreas
• Low blood sugar, especially when combined with a sulfonylurea
• Acute kidney injury, usually from dehydration caused by vomiting or diarrhea
• Gallbladder problems, including gallstones
• Injection-site lumps with the extended-release form
• For the extended-release Bydureon form, a boxed warning for thyroid C-cell tumors based on rodent studies, which is not carried by the twice-daily Byetta

How does exenatide compare to semaglutide, tirzepatide, and liraglutide?

Exenatide is the original GLP-1 drug, and the medicines that followed have largely surpassed it on both effectiveness and convenience. The clearest difference is potency, especially for weight. Exenatide produces relatively modest reductions in blood sugar and weight. The newer drugs reached larger average weight loss in their weight-management trials:

These figures come from separate trials rather than direct head-to-head studies, but the trend is consistent: the newer agents lower weight and blood sugar more. Mechanism is part of the story. Exenatide, liraglutide, and semaglutide all act only on the GLP-1 receptor, while tirzepatide activates a second gut-hormone receptor, GIP, as well, which is thought to contribute to its larger effect. Exenatide is also distinctive in its origin, since it is based on the lizard peptide exendin-4, whereas liraglutide and semaglutide are engineered from human GLP-1. Convenience shifted too. Exenatide started as a twice-daily injection, with a later once-weekly version, while liraglutide is once-daily and both semaglutide and tirzepatide are once-weekly, and semaglutide additionally comes as a daily pill. Finally, the class has moved well beyond blood sugar. Liraglutide and semaglutide carry cardiovascular indications, semaglutide is also approved for chronic kidney disease and fatty liver disease, and tirzepatide is approved for obstructive sleep apnea. Exenatide's brands, by contrast, were discontinued in the U.S. in 2024, and it is effectively a first-generation drug that the newer options have replaced.

Evidence strength

FDA approved: It is approved by the FDA for type 2 diabetes and was the first medicine in the GLP-1 class, supported by its randomized controlled trial program.

Sources: FDA prescribing information for Bydureon BCise (exenatide) and Mounjaro (tirzepatide); the SCALE (Pi-Sunyer et al., 2015, DOI: 10.1056/NEJMoa1411892), STEP 1 (Wilding et al., 2021, DOI: 10.1056/NEJMoa2032183), and SURMOUNT-1 (Jastreboff et al., 2022, DOI: 10.1056/NEJMoa2206038) weight-management trials in the New England Journal of Medicine and a review of the development of exenatide from Gila monster venom, indexed on PubMed; and the 2024 U.S. discontinuation notice. This document is educational and does not constitute medical advice.